Literature DB >> 8384658

Clinical efficacy of azithromycin in lower respiratory tract infections.

G Morandini1, M Perduca, G Zannini, M P Foschino, G Miragliotta, N S Carnimeo.   

Abstract

A total of 51 patients with acute exacerbation of chronic bronchitis and pneumonia were enrolled: 27 treated with azithromycin (500 mg once a day for 3 days), and 24 with roxithromycin (150 mg every 12 hours for 7 days). The two regimens were equally effective, with clinical cure in 80% and 72% of patients respectively. Bacteriological eradication on day 19-23 was obtained in 7/11 cases (64%) and in 6/13 cases (46%) in the two groups, respectively. No side effects occurred in patients treated with azithromycin, while they occurred in the roxithromycin group (2 vomiting and 1 gastritis). Clinical and bacteriological efficacy, excellent tolerability, simplified dosage (single daily dose) and short-course (3 days) therapeutic regimen make azithromycin, in our experience, efficacious for the treatment of acute exacerbation of chronic bronchitis and community-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384658     DOI: 10.1080/1120009x.1993.11739206

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  3 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 2.  Azithromycin for acute lower respiratory tract infections.

Authors:  Malinee Laopaiboon; Ratana Panpanich; Kyaw Swa Mya
Journal:  Cochrane Database Syst Rev       Date:  2015-03-08

Review 3.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.